Article Text

Download PDFPDF
Stratification of Venous Thromboembolism Risk in Ovarian Cancer Patients During Chemotherapy
  1. Liliana Mereu*,
  2. Saverio Tateo,
  3. Catherine Klersy,
  4. Eva Martinotti Gabellotti and
  5. Franco Polatti
  1. * Department of Obstetrics and Gynecology, Ospedale Sacro Cuore, Negrar-Verona;
  2. Department of Obstetrics and Gynecology, and
  3. Biometry and Clinical Epidemiology Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  1. Address correspondence and reprint requests to Liliana Mereu, Department of Obstetrics and Gynecology, Ospedale Sacro Cuore, Via Don A Sempreboni 5, 37024 Negrar, Verona, Italy. E-mail: liliana.mereu{at}sacrocuore.it.

Abstract

Background: The prevalence of venous thromboembolism (VTE) in ovarian cancer during first-line chemotherapy (CHT) ranges between 6.4% and 10.6%. Identification of the susceptible population is crucial for effective thromboprophylaxis.

Methods: We performed a retrospective study of all our patients with epithelial ovarian cancer who underwent ambulatory first-line CHT between 1990 and 2004. Data were collected regarding age, body mass index (BMI), previous deep vein thrombosis, pulmonary embolism (PE), menopause status, FIGO stage, grade, histology, type of surgery, residual disease, and CHT. Univariable and multivariable regression analyses were performed to assess independent prognostic factors for VTE/PE to calculate a prognostic index (PI).

Results: Of 203 patients, 16 (7.8%) had symptomatic VTE: 15 deep vein thrombosis and 1 PE. Multivariable regression analysis found that age (P = 0.01), BMI (P = 0.01), and stage (P = 0.05) were independent prognostic factors for VTE. Age, BMI, and stage were used to calculate the PI: 0.285 × age + 0.555 × BMI + 1.110 × stage. The PI was dichotomized according to its median cutoff (5.8) to define a low (3.8% at 6 months) and a high (11.3%) VTE incidence group.

Conclusions: Age, BMI, and stage permit to identify ovarian cancer patients with a high risk in developing symptomatic VTE during CHT.

  • Venous thromboembolism
  • Ovarian cancer
  • Chemotherapy
  • Prognostic index

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.